Fig 2: Immunohistochemical staining of uromodulin, CFH and a-SMA in kidneys on a series of days. (a) Representative micrographs (40×, bar = 25 µm) and (b) quantification of positive staining on kidney sections on different days as indicated (n = 3). ** p < 0.01 between the two groups. CP, cisplatin.

Fig 3: Uromodulin expression during cisplatin (CP)-induced AKI-to-CKD transition in rats. (a) Relative expression of uromodulin in kidney after normalization with GAPDH. (b) Urinary uromodulin level normalized by UCRE (n = 6). (c) Representative Western blots of uromodulin, CFH and a-SMA. The relative protein expression of (d) uromodulin, (e) CFH and (f) a-SMA to GAPDH at different time points (n = 3). Data are presented as means ± SD. * p < 0.05 and ** p < 0.01 between the two groups.

Fig 4: Interaction between uromodulin and CFH in rat kidneys and complement activation during AKI-to-CKD transition. (a) Total protein lysates of normal rat kidneys were immunoprecipitated using an antibody against uromodulin and immunoblotted against CFH. (b) Representative micrographs (40×, bar = 25 µm) and (c) quantification of positive-stained C3 on kidney sections on different days as indicated (n = 3). * p < 0.05, ** p < 0.01 between the two groups. CP, cisplatin.

Fig 5: CFH expression during cisplatin (CP)-induced AKI-to-CKD transition in rats. Relative expression of CFH mRNA in (a) liver and (c) kidney after normalization with GAPDH. (b) Quantification of serum CFH level by ELISA with a 500-fold dilution of serum. Data are presented as means ± SD. * p < 0.05 and ** p < 0.01 between the two groups.